Sotorasib(Amgen)은 Locally Advanced Lung Non-Small Cell Car 표적 ADC로, Colorectal Cancer; Resectable Colorectal Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: binds to G12C mutant KRAS with high affinity and suppresses nucleotide exchange and MAPK signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 0. PK: t½ 5.2 h. 차별점: first-in-class KRAS G12C inhibitor, has demonstrated substantial clinical efficacy in KRAS G12C-mutant malignancies but is frequently.
Locally Advanced Lung Non-Small Cell Car
Colorectal Cancer; Resectable Colorectal Carcinoma
Recruiting
bispecific TOP1i ADC with promising anti-tumor activity and enhanced t
biodistribution
first-in-class KRAS G12C inhibitor, has demonstrated substantial clinical efficacy in KRAS G12C-mutant malignancies but is frequently
binds to G12C mutant KRAS with high affinity and suppresses nucleotide exchange and MAPK signaling
apoptosis and suppressing proliferative capacity, resulting in impaired epithelial barrier integrity
biomarker-guided treatment algorithms will be essential
resistance mechanisms are delineated into on-target pocket alterations and off-target bypass signaling, involving the reactivation of the MA
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Sotorasib(Amgen)은 Locally Advanced Lung Non-Small Cell Car 표적 ADC로, Colorectal Cancer; Resectable Colorectal Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: binds to G12C mutant KRAS with high affinity and suppresses nucleotide exchange and MAPK signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 0. PK: t½ 5.2 h. 차별점: first-in-class KRAS G12C inhibitor, has demonstrated substantial clinical efficacy in KRAS G12C-mutant malignancies but is frequently.
Locally Advanced Lung Non-Small Cell Car
Colorectal Cancer; Resectable Colorectal Carcinoma
Recruiting
bispecific TOP1i ADC with promising anti-tumor activity and enhanced t
biodistribution
first-in-class KRAS G12C inhibitor, has demonstrated substantial clinical efficacy in KRAS G12C-mutant malignancies but is frequently
binds to G12C mutant KRAS with high affinity and suppresses nucleotide exchange and MAPK signaling
apoptosis and suppressing proliferative capacity, resulting in impaired epithelial barrier integrity
biomarker-guided treatment algorithms will be essential
resistance mechanisms are delineated into on-target pocket alterations and off-target bypass signaling, involving the reactivation of the MA
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.